Pembrolizumab vs Nivolumab
## Overview
Pembrolizumab (Keytruda) and nivolumab (Opdivo) are both PD-1 (programmed cell death protein 1) checkpoint inhibitors that block the PD-1/PD-L1 axis, releasing suppression of anti-tumor T-cell immunity. Both are landmark immunotherapy agents; their indication profiles are vast and partially overlapping, but differ in dosing schedules, companion diagnostic requirements, and specific combinations.
## Mechanism of Action
Both are humanized IgG4 monoclonal antibodies that bind PD-1 on T cells, preventing its interaction with PD-L1 (expressed on tumor cells and APCs) and PD-L2. By blocking this inhibitory checkpoint, they unleash anti-tumor T-cell cytotoxicity.
## Pharmacokinetics
Pembrolizumab: IV every 3 or 6 weeks, half-life ~26 days, non-linear PK at low doses but near-linear at therapeutic doses. Nivolumab: IV every 2, 4, or 6 weeks, half-life ~27 days.
## Key Indications and FDA Approvals
Both have extensive indication lists across many tumor types. Pembrolizumab has a unique tumor-agnostic approval for any MMR-deficient or MSI-H solid tumor — the first histology-independent cancer approval by the FDA. Both are approved for melanoma, NSCLC, urothelial carcinoma, head and neck squamous cell carcinoma, and others.
Nivolumab is uniquely combined with ipilimumab (CTLA-4 inhibitor) in multiple tumor types (melanoma, NSCLC, mesothelioma, RCC, colorectal cancer MSI-H), giving it a broader combination regimen footprint.
Pembrolizumab typically requires PD-L1 expression testing (TPS ≥1% or ≥50% thresholds depending on indication) for certain approvals, while nivolumab + ipilimumab is approved for RCC regardless of PD-L1 expression.
## Immune-Related Adverse Events (irAEs)
Both cause irAEs: pneumonitis, colitis, hepatitis, endocrinopathies (thyroid dysfunction, adrenal insufficiency, diabetes mellitus), dermatitis. The irAE incidence and spectrum are broadly similar between PD-1 inhibitors.
## Key Takeaways
- Both anti-PD-1 antibodies with equivalent mechanism and broadly similar efficacy across tumor types
- Pembrolizumab: tumor-agnostic MMR-d/MSI-H approval; dominant in pembrolizumab+chemotherapy regimens
- Nivolumab: established dual checkpoint (nivo+ipi) combinations; unique indication set
- Dosing: pembrolizumab q3w or q6w; nivolumab q2w, q4w, or q6w
결론
For most PD-1-eligible tumor types, pembrolizumab and nivolumab have similar efficacy as single agents. Pembrolizumab is preferred for PD-L1-high NSCLC and MSI-H/MMR-deficient tumors (unique tumor-agnostic indication). Nivolumab is preferred when dual checkpoint blockade with ipilimumab is indicated (melanoma, RCC, mesothelioma, MSI-H colorectal).